FCGR2A

Across TCGA pan-cancer cohorts, FCGR2A RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of FCGR2A’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where FCGR2A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FCGR2A is over-expressed in tumor, although a few such as LUSC and LUAD show the opposite, repressed pattern.

KIRC, HNSC, and THCA are the cancer types where FCGR2A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FCGR2A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+2.260	<.001	12	view →
HNSC	Female	III,IV	+2.114	<.001	12	view →
THCA	Male	III,IV	+1.442	<.001	11	view →
LUSC	Female	All	−1.679	<.001	8	view →
STAD	All	II,III,IV	+1.420	<.001	8	view →
LUAD	All	II,III,IV	−0.734	<.001	8	view →
KIRP	Male	All	+1.432	<.001	7	view →
LIHC	All	II,III,IV	+1.004	<.001	7	view →
BLCA	All	IV	+1.029	.009	6	view →
COAD	All	II,III,IV	+0.657	.001	6	view →
BRCA	Female	All	+0.647	<.001	6	view →
ESCA	All	All	+1.895	.008	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

FCGR2A–KIRC

Open the KIRC breakdown →